France's AAA makes acquisition, gains orphan status for Gallium-68 DOTATATE

French molecular nuclear medicines specialist Advanced Accelerator Applications SA (AAA) has acquired Imaging Equipment and received orphan drug designation for Gallium-68 DOTATATE.

The acquisition of Imaging Equipment, financial terms of which were not disclosed, gives AAA its first direct sales presence in the UK and Ireland, expands its specialist nuclear medicine capabilities and gives it the rights to IEL’s licensed SPECT radiopharmaceutical diagnostic product, IELMAG3.

IEL generated sales of almost £6.77 million ($11.3 million) for full-year 2013, up 58% on 2012. The UK’s nuclear medicine market is one of the largest in Europe, with annual sales of more than 120 million euros ($165.7 million).